Schizophrenia
Conditions
Brief summary
Primary objective: To assess the efficacy of adding raloxifene as an adjunct to antipsychotic treatment to improve negative symptoms of schizophrenia in postmenopausal women. This is a double-blind, randomized, placebo-controlled study of raloxifene as adjuvant treatment to antipsychotic treatment. Treatment period of 12 weeks. The primary result obtained is that women treated with 60 mg of raloxifene compared to those treated with a placebo show greater improvement in psychotic symptoms. The investigators also found improved response in some aspects of social functioning and neuropsychological functioning.
Interventions
DRUGraloxifene
Dose of raloxifene hydrochloride will be: 60mg /day. Patients are required to continue taking their regular medications throughout the duration of the study. No changes in dose will be required during the study period. Double-blind treatment will continue for 12 weeks.
Sponsors
Fundació Sant Joan de Déu
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
FEMALE
Age
40 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Diagnosis of schizophrenia (DSM-IV criteria) * Postmenopausal patients. Postmenopause is defined as after a period of one year of spontaneous amenorrhea and a serum follicle stimulating hormone (FSH) level \> 20IU/L. * Stable doses of their current antipsychotic medication for at least a month prior to study initiation. * Presence of significant negative symptoms (defined as one or more negative symptom score greater than 4 in the PANSS scale) (Kay 1987) * Patients have to give written informed consent to participate in the study.
Exclusion criteria
* Patients with a substance abuse/dependence diagnosis in the previous six months. * Mental retardation. * Endocrine abnormalities, acute or chronic liver disease, impaired kidney function. * History of thromboembolism, breast cancer, abnormal uterine bleeding, history of cerebrovascular accident. * Patients taking hormone replacement therapy. * Patients taking mood stabilizer medication that cannot be discontinued.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary efficacy end-point will be the change in the score of the PANSS negative subscale from baseline to follow-up assessment. | — |
Secondary
| Measure | Time frame |
|---|---|
| Patients social and neuropsychological functioning will be evaluated, comparing baseline ratings to end-point. | — |
Countries
Spain
Outcome results
None listed